Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.'s Transaction with Neurocrine is Fair to Public Shareholders

MILWAUKEE, April 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Soleno (NASDAQ: SLNO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Neurocrine. Click here to learn how to join our investigation and obtain additional...